Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers

OBJECTIVE: The myosin-binding protein C (MYBPC3) c.927-2A>G founder mutation accounts for >90% of sarcomeric hypertrophic cardiomyopathy (HCM) in Iceland. This cross-sectional observational study explored the penetrance and phenotypic burden among carriers of this single, prevalent founder mut...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Heart
Main Authors: Adalsteinsdottir, Berglind, Burke, Michael, Maron, Barry J, Danielsen, Ragnar, Lopez, Begoña, Diez, Javier, Jarolim, Petr, Seidman, Jonathan, Seidman, Christine E., Ho, Carolyn Y, Gunnarsson, Gunnar Th
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Heart Failure and Cardiomyopathies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7174027/
https://ncbi.nlm.nih.gov/pubmed/32341788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/openhrt-2019-001220
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados